Astrazeneca (AZN. L) improved the early pipelines Wednesday by buying private holdings of U.S. biotechnology company AlphaCore pharmaceutical companies are developing a new type of experimental cholesterol drug heart medication.
British drugmaker MedImmune unit acquired financial details were not disclosed.
Astrazeneca PLC Soriot PASCAL's new chief executive, said last month that he planned to set up the company's drugs pipeline dredging dozens more preferential, cardiovascular disease and metabolic disease a particular priority.
Cardiovascular and metabolic disease, is astrazeneca's three core therapeutic areas -, as cancer and respiratory/inflammation - but in this case, the company currently has a few experimental compound.
AlphaCore will help plug-in gap, although it does not provide any readily marketable products for many years. The leading drug candidate ACP - 501, liver enzyme source sex LCAT gene engineering, only completed the first phase in phase I clinical trials last year.
Drugs have been approved for sale before, need to go through three stages of lengthy test.
Hope is ACP - 501, and will help in the management of cholesterol to reduce the risk of heart attack and stroke. A rare genetic disease, familial LCAT deficiency of LCAT enzyme exists, it can also play a role.
He said: "in this aspect of the continuous development of science, we are committed to exploring ways unique, may lead to a new combination or independent living with chronic and acute treatment and cardiovascular disease, said:" the MedImmune's head Bahija Jallal.
Other News:
4 former BizJet execs charged with foreign bribery
AstraZeneca buys early-stage U.S. biotech firm
Rising Home Prices And Falling Unemployment: Don't Trust the Numbers
U.S. General Says North Korea Situation Is 'Volatile' and 'Dangerous'
Analyst believes HP won't roll out any new broad initiatives until new chairman
Asian shares mark time before banks, U.S. jobs data
Dell warns of risks of remaining a public company
Official: Obama proposes cuts to Social Security
